Literature DB >> 24488625

The effects of p53 Arg72Pro polymorphism on glioma susceptibility: a meta-analysis.

Weijie Zhu1, Lei Lu, Yi Li, Jie Yao, Bainan Xu.   

Abstract

The potentially functional polymorphism Arg72Pro in p53 gene has been implicated in glioma risk, but published studies have mixed findings. The aim of current investigation was to identify whether p53 Arg72Pro polymorphism was significantly associated with the risk of glioma. By searching the databases of PubMed, EMBASE, and Web of Science, our meta-analysis included ten eligible studies consisting of 2,645 glioma cases and 3,920 control subjects. The association between p53 Arg72Pro polymorphism and glioma risk was assessed by summarizing the odds ratios (ORs) with the corresponding 95% confidence intervals (CIs). We found that there was no overall risk of glioma in relation to any genetic model of p53 Arg72Pro polymorphism. Similar results were implicated in the analyses which are subgrouped by ethnicity and source of controls. This nonsignificant association remained stable when analyses were restrained to the studies consistent with HWE. In conclusion, our meta-analysis, based on the combined data from published papers before May 2013, reveals no evidence for significant association between p53 Arg72Pro polymorphism and glioma risk.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24488625     DOI: 10.1007/s13277-013-1494-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  28 in total

Review 1.  The molecular epidemiology of gliomas in adults.

Authors:  Margaret Wrensch; James L Fisher; Judith A Schwartzbaum; Melissa Bondy; Mitchel Berger; Kenneth D Aldape
Journal:  Neurosurg Focus       Date:  2005-11-15       Impact factor: 4.047

2.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

3.  Absence of germline and somatic p53 alterations in children with sporadic brain tumors.

Authors:  C Portwine; S Chilton-MacNeill; C Brown; E Sexsmith; J McLaughlin; D Malkin
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

4.  Gamma-radiation sensitivity and risk of glioma.

Authors:  M L Bondy; L E Wang; R El-Zein; M de Andrade; M S Selvan; J M Bruner; V A Levin; W K Alfred Yung; P Adatto; Q Wei
Journal:  J Natl Cancer Inst       Date:  2001-10-17       Impact factor: 13.506

5.  Adult glioma incidence trends in the United States, 1977-2000.

Authors:  Kenneth R Hess; Kristine R Broglio; Melissa L Bondy
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

6.  P53 codon 72 Arg/Pro polymorphism and glioma risk: an updated meta-analysis.

Authors:  Fang He; Yi Xia; Huafeng Liu; Jin Li; Chao Wang
Journal:  Tumour Biol       Date:  2013-07-17

7.  TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas.

Authors:  Vítor Lima-Ramos; Luís Pacheco-Figueiredo; Sandra Costa; Fernando Pardal; Ana Silva; Júlia Amorim; José Manuel Lopes; Rui Manuel Reis
Journal:  Cancer Genet Cytogenet       Date:  2008-01-01

8.  Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults.

Authors:  Preetha Rajaraman; Sophia S Wang; Nathaniel Rothman; Merideth M Brown; Peter M Black; Howard A Fine; Jay S Loeffler; Robert G Selker; William R Shapiro; Stephen J Chanock; Peter D Inskip
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-08       Impact factor: 4.254

9.  Mutagen sensitivity and risk of gliomas: a case-control analysis.

Authors:  M L Bondy; A P Kyritsis; J Gu; M de Andrade; J Cunningham; V A Levin; J M Bruner; Q Wei
Journal:  Cancer Res       Date:  1996-04-01       Impact factor: 12.701

10.  TP53 and RPA3 gene variations were associated with risk of glioma in a Chinese Han population.

Authors:  Tianbo Jin; Jiayi Zhang; Gang Li; Shanqu Li; Bo Yang; Chao Chen; Linbo Cai
Journal:  Cancer Biother Radiopharm       Date:  2013-04       Impact factor: 3.099

View more
  4 in total

Review 1.  Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.

Authors:  Mohammad Haroon Khan; Aftab Khalil; Hamid Rashid
Journal:  Genet Res (Camb)       Date:  2015-04-17       Impact factor: 1.588

2.  p53 p.Pro72Arg (rs1042522) and Mouse Double Minute 2 (MDM2) Single-Nucleotide Polymorphism (SNP) 309 Variants and Their Interaction in Chronic Lymphocytic Leukemia(CLL): A Survey in CLL Patients from Western Iran.

Authors:  Nazanin Jalilian; Yosra Maleki; Ebrahim Shakiba; Mozafar Aznab; Ziba Rahimi; Mehdi Salimi; Zohreh Rhimi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2021-07-01

3.  Association of TP53 rs1042522 C>G Polymorphism with Glioma Risk in Chinese Children.

Authors:  Fan Liao; Li Yuan; Jinhong Zhu; Wei Chen; Yemu Zhao; Jing He
Journal:  Biomed Res Int       Date:  2022-08-13       Impact factor: 3.246

4.  lncRNA CCAT2 Enhanced Resistance of Glioma Cells Against Chemodrugs by Disturbing the Normal Function of miR-424.

Authors:  Jun Ding; Lin Zhang; Shiwen Chen; Heli Cao; Chen Xu; Xuyang Wang
Journal:  Onco Targets Ther       Date:  2020-02-17       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.